Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000045795 | SCV000073808 | uncertain significance | Hereditary breast and ovarian cancer syndrome | 2015-07-31 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine with arginine at codon 3115 of the BRCA2 protein (p.Lys3115Arg). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and arginine. This variant is present in population databases (rs276174923, 0.04%) but has not been published in the literature. This variant has been reported in individuals in the Breast Cancer Information Core database (PMID: 10923033). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. In summary, this is a rare missense change that is not predicted to affect protein function or cause disease. However the evidence is insufficient at this time to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000223579 | SCV000272968 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-03-05 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: Insufficient or conflicting evidence |
Counsyl | RCV000114092 | SCV000487764 | uncertain significance | Breast-ovarian cancer, familial 2 | 2015-11-21 | criteria provided, single submitter | clinical testing | |
Color | RCV000223579 | SCV000689190 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-08-30 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000114092 | SCV000147612 | uncertain significance | Breast-ovarian cancer, familial 2 | 2010-09-18 | no assertion criteria provided | clinical testing |